AUS
NZ
UK
CA
USA
IND
_07_12_2023_11_05_52_936360.jpg)
In 2024, the ResMed CDI share price, an ASX value stock, has surged by 31.1%, reflecting a strong performance throughout the year. In contrast, the Netwealth Group Ltd share price has experienced a notable recovery, rebounding approximately 87.1% from its 52-week low.
ResMed (ASX:RMD)
ResMed, originally established in Australia in 1989 by Peter Farrell, is now headquartered in San Diego, California. The company specializes in medical equipment, particularly cloud-connectable continuous positive airway pressure (CPAP) machines used to treat obstructive sleep apnea (OSA). ResMed's primary listing is on the New York Stock Exchange, but it is also available on the ASX.
Operating globally with over 10,000 employees across more than 140 countries, ResMed's business is divided into two main segments: Sleep and Respiratory Care, and Software as a Service (SaaS). The Sleep and Respiratory Care segment focuses on advanced CPAP machines for sleep apnea and other respiratory care needs. The SaaS unit provides software solutions that support durable or home medical equipment, enhancing out-of-hospital care.
ResMed's large digital health network, driven by its cloud-connected devices, enables the company to harness insights from both hardware (such as masks and humidifiers) and SaaS data. This approach aims to improve patient outcomes and reduce overall healthcare costs.
Netwealth Group Ltd (ASX:NWL)
Netwealth, founded in 1999, operates as a wealth management business, offering a platform for financial planners to manage client investments. As of 2024, Netwealth services over 140,000 account holders and administers more than $88 billion in funds.
Netwealth's platform stands out for its scale and user-friendly interface, allowing clients to manage investments, track performance, and access reports through a single, integrated dashboard.
Valuation Insights
ResMed, being a growth-oriented company, can be evaluated using various financial metrics. Currently, the ResMed share price has a price-to-sales ratio of 4.74x. This is below its 5-year average of 6.13x, suggesting that the shares are trading at a lower multiple compared to their historical average. While this valuation metric provides some insight, it's important to consider additional factors and valuation techniques to get a comprehensive view of the company's financial health.
For Netwealth, the price-to-sales ratio is 21.70x, compared to its 5-year average of 20.14x. This indicates that the shares are trading above their historical average. While this multiple offers a snapshot of the company’s valuation, further analysis through methods such as Discounted Cash Flow (DCF) and Dividend Discount Models (DDM) can provide a more detailed understanding.
Both ResMed and Netwealth Group Ltd have shown significant performance in their respective areas. ResMed's growth and global presence, coupled with its innovative health solutions, contrast with Netwealth’s strong recovery and scalable wealth management platform. Each company's valuation metrics offer useful insights but should be considered alongside other factors for a well-rounded investment analysis.
